aTyr Pharma, Inc. Stock Price, News & Analysis

aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company, announced participation in four virtual investor conferences in March 2021. Dr. Sanjay S. Shukla, President and CEO, will deliver a corporate overview and engage in a panel discussion on immuno-oncology at the ROTH Conference. Key events include the H.C. Wainwright Global Life Sciences Conference (March 9-10), the ROTH Conference (March 15-17), the Oppenheimer Healthcare Conference (March 17), and the Maxim Group Conference (March 17-18). Presentations will be available for registered attendees and a replay will be accessible on the company's website.

aTyr Pharma, Inc. (Nasdaq: LIFE) has announced the initiation of two new discovery programs from its tRNA synthetase platform, focusing on Alanyl-tRNA Synthetase (AARS) and Aspartyl-tRNA Synthetase (DARS) fragments in immunology, fibrosis, and cancer. This effort aims to explore how these fragments affect natural killer (NK) cell biology, potentially leading to innovative therapies. The announcement follows a successful poster presentation at the SLAS 2021 conference, showcasing the interaction of these fragments with immune cells. aTyr’s current pipeline includes ATYR1923, targeting the Neuropilin-2 receptor.

aTyr Pharma (Nasdaq: LIFE) will present a corporate overview at the BIO CEO & Investor Digital Conference from February 16-18, 2021. Dr. Sanjay S. Shukla, President and CEO, will lead the presentation, available on-demand for attendees. A replay will be accessible on the company's website for 30 days post-event. In addition, management will hold virtual one-on-one meetings during the conference, which can be arranged through the partnering system or via email. aTyr focuses on innovative therapies targeting the extracellular functions of tRNA synthetases.

aTyr Pharma, Inc. (Nasdaq: LIFE) announced the presentation of preclinical findings at the Virtual Keystone Symposia regarding Neuropilin-2 (NRP2) expression on immune cells in the tumor microenvironment. The poster highlights NRP2's significant role in cancer progression, particularly through its high expression in myeloid derived suppressor cells and tumor-associated macrophages. The findings may support the development of NRP2-targeted cancer therapeutics, including aTyr's lead antibody, ATYR2810. The live Q&A will be held on January 27, 2021.

SAN DIEGO, Jan. 22, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma (Nasdaq: LIFE) announced its participation in the virtual Society for Laboratory Automation and Screening Digital International Conference from January 25-27, 2021. The company will present a poster detailing a mass spectrometry proteomics method that identifies receptor targets for tRNA synthetase fragments AARS and DARS. Findings suggest potential applications in immunology, cancer, and fibrosis, supporting aTyr’s innovative biology platform and drug development efforts.

aTyr Pharma announced that its partner Kyorin Pharmaceutical has completed the final subject visit in the Phase 1 clinical trial of ATYR1923, triggering a milestone payment to aTyr. The trial evaluated safety and pharmacokinetics in 32 healthy Japanese male volunteers and aims to initiate patient trials for interstitial lung disease in Japan. Kyorin's progress with ATYR1923 is encouraging for aTyr, which is also conducting a Phase 1b/2a trial for pulmonary sarcoidosis and has previously tested ATYR1923 in COVID-19 patients.

aTyr Pharma (Nasdaq: LIFE) has announced that its President and CEO, Sanjay S. Shukla, M.D., M.S., will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 AM ET and will be accessible on the company's website for 90 days post-event. Additionally, the company will engage in virtual one-on-one meetings during the J.P. Morgan Healthcare Conference week (January 11-15, 2021), facilitated by the Biotechnology Innovation Organization.

aTyr Pharma announced positive topline results from its Phase 2 trial of ATYR1923 in hospitalized COVID-19 patients. The study met its primary safety endpoint with ATYR1923 being well-tolerated at doses of 1.0 and 3.0 mg/kg. Notably, patients receiving the 3.0 mg/kg dose demonstrated a median recovery time of 5.5 days, and 83% recovered in less than a week. The trial involved 32 patients and assessed safety and preliminary efficacy against a placebo. The company plans to provide further insights during a conference call on January 4.

aTyr Pharma (Nasdaq: LIFE) has announced the completion of target enrollment in its Phase 1b/2a clinical trial for ATYR1923, aimed at treating pulmonary sarcoidosis, with 36 patients enrolled. Results are anticipated in Q3 2021, potentially guiding future studies in interstitial lung diseases (ILD). ATYR1923 targets immune modulation to improve lung function with reduced toxicity compared to existing treatments. Additionally, a Phase 2 trial for COVID-19 patients has completed enrollment, with topline data expected soon.